Senotherapeutics: emerging strategy for healthy aging and age-related disease.

Cellular senescence (CS) is one of hallmarks of aging and accumulation of senescent cells (SCs) with age contributes to tissue or organismal aging, as well as the pathophysiologies of diverse age-related diseases (ARDs). Genetic ablation of SCs in tissues lengthened health span and reduced the risk of age-related pathologies in a mouse model, suggesting a direct link between SCs, longevity, and ARDs. Therefore, senotherapeutics, medicines targeting SCs, might be an emerging strategy for the extension of health span, and prevention or treatment of ARDs. Senotherapeutics are classified as senolytics which kills SCs selectively; senomorphics which modulate functions and morphology of SCs to those of young cells, or delays the progression of young cells to SCs in tissues; and immune-system mediators of the clearance of SCs. Some senolytics and senomorphics have been proven to markedly prevent or treat ARDs in animal models. This review will present the current status of the development of senotherapeutics, in relation to aging itself and ARDs. Finally, future directions and opportunities for senotherapeutics use will discussed. This knowledge will provide information that can be used to develop novel senotherapeutics for health span and ARDs. [BMB Reports 2019; 52(1): 47-55].

INTRODUCTION

Cellular senescence (CS) is initially defined as an irreversible growth arrest of normal somatic cells, and has been proposed to contribute to tissue and organismal aging itself, and to be an intrinsic safeguard against tumor progression (1). SCs have been shown to have diverse phenotypes, including cellular flattening and hypertrophy, senescence-associated β-galactosidase activity (SAβG), senescence-associated secretory phenotype (SASP), resistance to apoptotic cell death, alterations in nuclear structure and senescence-associated heterochromatic foci (SAHF), mitochondrial expansion, and signaling events, including upregulation of cell cycle inhibitors and -pro-survival effectors (2). SCs accumulated in various tissues in mice with age, and comprised 5–40% of the total cells, depending on the tissue types (3). Although their number are relatively small in tissues, SCs can cause extensive dysfunction of the microenvironment and damage to surrounding cells and tissues, due to their pro-inflammatory senescence-associated secretory phenotype (SASP). Accumulating evidence suggests that CS plays an important role in diverse biological processes, such as embryonic development, diabetes, host immunity, wound healing, tissue renewal, as well as fibrosis, cardiovascular diseases, and cancer (4).

Since aging is one of major risk factors of human diseases, a variety of aging interventions have been developed to extend health span and to prevent or treat ARDs in in vitro and in vivo experimental models. Caloric restriction (CR) is the only intervention shown to increase health span as well as to decrease the risk of ARDs in nonhuman primates (5). Recently, clinical trials of CR in non-obese humans revealed that a 15% lower calorie intake for 2 years delayed metabolism accompanied by reduced oxidative damage, suggesting that CR could also slow down the aging process in humans (6). Although CR can enhance healthy aging, the inconvenience of most subjects to maintain CR for a longtime limits its application. Therefore, caloric restriction mimetics (7), and calorie restriction diets or fasting-mimicking diets (8) have been proposed as alternatives. Elucidation of the mechanisms by which aging is regulated also suggested a variety of compounds and medicines, including sirtuin activators (9), AMP dependent protein kinase (AMPK) activators (10), mammalian target of rapamycin (mTOR) inhibitors (11), autophagy activators (12), that might be applicable for use in aging intervention. In addition, the use of geroprotectors, compounds and medicines that slow down aging, and thus lengthen the lifespan of model organisms has also been proposed (13). In present, a curated database of geroprotectors is available, and includes 259 compounds in 13 animal models from yeast to human, obtained from 2,408 literature (http://geroprotectors.org/). An old story tells the rejuvenation effects of young blood. Heterochronic parabiosis, in which an aged mouse and a young one were joined surgically, revealed that some factors in young blood, such as growth differentiation factor 11 with controversial reports and oxytocin enhanced tissue regeneration, and led to improvement of aging phenotypes (14). Similarly, transfusion of young serum also retarded age-related impairments in cognitive function and synaptic plasticity in aged mice (15, 16).

Although CS is one of hallmarks of aging (17), and accumulation of SCs with age has been suggested to be associated with aging and ARDs (18), direct evidence of a causal relationship between CS and aging or ARDs has only recently been validated in rodent models. Furthermore, senotherapeutics, have been implicated as novel strategies for aging intervention in applications designed to extend healthy aging and to prevent or treat ARDs.

DIRECT LINKAGE OF CS TO AGING AND ARDs

Baker et al., reported the first direct evidence of a direct causal relationship of CS to ARDs in 2011 (19). For the clearance of senescent cells in mice, a transgenic strategy, was employed, using INK-ATTAC derived from p16, a well-known marker of CS, in which senescent cells were selectively eliminated by apoptotic cell death upon administration of AP20187. The INK-ATTAC transgenic mice were bred onto a BubR1-progeroid mouse background to obtain BubR1;INK-ATTAC mice. The authors demonstrated that the animals treated with AP20187 from early (weaning time) or late (5 months) in life, had reduced numbers of p16-positive senescent cells, and progression of p16-mediated age-related phenotypes in adipose tissue and muscle was delayed (19). Five years later, Baker et al., reported more concrete evidence of the direct linkage of CS to aging itself and ARDs (20). This time, they demonstrated effects of the clearance of p16-positive senescent cells in both male and female INK-ATTAC transgenic mice of two distinct genetic backgrounds (C57BL/6 and mixed). AP20187 treatment from 12 months to 18 months increased the median lifespan of both C57BL/6 and mixed background mice by 24%, and prolonged the heath span in C57BL/6 mice by 18%, and by 25% in mixed background mice. In addition, they demonstrated that AP20187 attenuated age-related functional and structural deterioration of multiple organs, without any detrimental side effects to adipose tissue, kidney, or heart (20). Genetic ablation of senescent cells, using the INK-ATTAC transgenic mice further revealed that clearance of p16-positive senescent cells improved age-related lipodystrophy (21), hepatic steatosis (22), age-related cardiac function and bone loss (23), and tau-mediated cerebral pathologies (24). Studies on another p16-based transgenic mouse, named the p16-trimodality reporter (p16-3MR) mouse, in which p16-positive senescent cells were cleared by treatment with ganciclovir, revealed that removal of senescent macrophages attenuated atherosclerotic plaque formation in LDLR−− background mice (25), and osteoarthritis (26). In addition to genetic clearance of senescent cells, transplanting senescent ear fibroblasts into the knee region induced osteoarthritis in mice (27). Transplanting relatively small numbers of senescent cells into young mice was reportedly sufficient to cause persistent physical dysfunction, as well as to spread cellular senescence to host tissues, which led to reduced survival (28). Therefore, these proof-of-principle experiments revealed the direct linkage of CS to aging and ARDs, and suggest that therapeutic interventions to remove senescent cells or block their effects might represent a novel strategy to lengthen health span and prevent or treat ARDs in human (20).

SENOLYTICS

Since elimination of SCs using genetic approaches mitigated aging and ARDs, pharmacological intervention targeting SCs, named as senotherapeutics, has been proposed. Senotherapeutics are classified as senolytics, which selectively kill SCs; senomorphics which modulate SCs by blocking SASP; and senoinflammation, the immune system-mediated clearance of SCs (Fig. 1).

Fig. 1

Senotherapeutics targeting SCs. CS induced by diverse factors is involved in many biological processes, embryonic development, tissue homeostasis, and tissue dysfunction, thus contributing to age-related pathologies and lifespan. Therefore, senotherapeutics targeting SCs is an emerging strategy of aging intervention for extension of health span and prevention and treatment of ARDs. Senotherapeutics is comprised of 3 classes: senolytics which kill SCs selectively; senomorphics which modulates or even reverses the phenotypes of SCs to those of young cells by interfering with triggers of CS, targeting SCs directly, or blocking SASP: and mediators of the immune-system clearance of SCs.

In 2015, Zhu et al., reported the first senolytics, dasatinib, a protein tyrosine kinase inhibitor, and quercetin, a plant flavonoid (29). Based on transcriptomic analysis, they discovered that SCs increased the expression of pro-survival networks, which led to resistance to apoptosis. The authors screened 46 candidate drugs for their ability to eliminate SCs in vitro and found that dasatinib was effective against senescent human preadipocytes, and that quercetin was effective against senescent human endothelial cells and mouse bone marrow-derived mesenchymal stem cells (BM-MSCs). Finally, they showed that combination of dasatinib and quercetin reduced SC burden in chronologically aged, radiation-exposed, and Ercc1-progeroid mice, which resulted in extension of health span and reduction of age-related pathologies (29). Their seminal demonstration on the feasibility of selectively ablating senescent cells by pharmacological intervention and the efficacy of senolytics for alleviating symptoms of frailty and extending health span in mice, prompted development of other senolytics.

Until now, seven classes of senolytics have been reported, including kinase inhibitors, a Bcl-2 family inhibitors, natural compounds, a p53 binding inhibitor, heat shock protein 90 (HSP90) inhibitors, UBX0101, and a histone deacetylase (HDAC) inhibitor (30) (Table 1). The combined administration of dasatinib and quercetin improved the pathologies of diverse ARDs, including cardiac aging (29), atherosclerosis (31), osteoporosis (23), pulmonary fibrosis (32), hepatic steatosis (22), and Alzheimer’s disease (24) by clearing SCs in the tissues. Recently, the combination of dasatinib and quercetin was reported to enhance physical function and to lengthen health span and lifespan in old mice (28).

Table 1

Senolytic candidates

Agents	Target/Pathway	Effective senescent cells	Outcomes in vivo	Ref.
Dasatinib + Quercetin	Pan-receptor tyrosine kinase/Multiple pathways	HUVECs	↓Atherosclerosis	22
		Preadipocytes	↓Osteoporosis	23
		MEFs	↓Hepatic steatosis	28
		BM-MSCs	↓Pulmonary fibrosis	29
			↑Exercise capacity	31
			↑Vasomotor function	32
			↑Cardiac function
			↑Lifespan
ABT-263	Bcl-2 family (Bcl-2, BCL-XL, Bcl-W)	HUVECs	↑Hematopoietic and muscle stem cell function	33
		IMR90	↓Atherosclerotic lesion formation	34
		MEFs
		WI-38
ABT-737	Bcl-2 family (Bcl-2, Bcl-xL, Bcl-W)	IMR90	↑Hair follicle stem cell function	35
			↓IR-induced lung injury
A1331852	Bcl-2 family (Bcl-xL)	HUVECs	↓Liver fibrosis	37
A1155463		IMR90
		Cholangiocytes
17-AAG Geldanamycin	HSP90	MEFs	↓Age-related symptoms	38
		MSCs	↑Health span
		IMR90
		HUVECs
		WI-38
Fisetin	PI3K/AKT	HUVECs	Not reported	36
Piperlongumine	Multiple pathways	WI-38	Not reported	39
Quercetin-3-D-galactose	Multiple pathways	HCAECs	Not reported	40
UBX0101	MDM2/p53	Chondrocytes	↓Osteoarthritis	26
Panobinostat	HDAC	NSCLC cell lines	Not reported	41
		HNSCC cell lines
FOXO4-DRI peptide	p53/p21/serpine	IMR90	↓Liver toxicity induced by doxorubicin	44
			↓Frailty
			↑Hair growth
			↑Renal function

Resistance of SCs to apoptotic cell death, due to upregulation of Bcl-2 and Bcl-xL suggested inhibitors of these anti-apoptotic proteins as useful candidates for senolytics. In this regard, ABT-263, ABT-737, A1331852, and A1155463 were reported as senolytic candidates in in vitro, as well as in in vivo models. ABT-263, which binds to the inhibitory domain of anti-apoptotic Bcl-2, Bcl-xL, and Bcl-W, effectively cleared SCs, senescent bone marrow hematopoietic stem cells (HSCs), and senescent muscle stem cells (MuSCs) from either irradiated or normally aged mice, and led to mitigation or rejuvenation of HSCs and MuSCs in both animal models (33). ABT-263 selectively decreased viability of some senescent cells, such as senescent human umbilical vein epithelial cells (HUVECs), IMR90 human lung fibroblasts, and murine embryonic fibroblasts (MEFs), but not human primary preadipocytes (34). ABT-263 eliminated senescent foam cell macrophages in atherosclerotic lesions, consequently blocking progression of atherosclerosis in LDLR−− mice (25). ABT-737 selectively killed senescent IMR90 cells induced by etoposide, H-Ras activation, and replication in vitro (35). ABT-737 treatment also efficiently cleared senescent lung epithelial cells of irradiated mice, and senescent epidermal cells of p14 transgenic mice, and resulted in an increase in hair follicle stem cell proliferation (35). A1331852 and A1155463, selective Bcl-xL inhibitors, induced apoptosis of irradiation-induced senescent HUVECs and IMR90 cells, but not of preadipocytes (36). A1331852 reduced liver fibrosis through depletion of senescent cholangiocytes and reduction of serum levels of SASP factors in primary sclerosing cholangitis model of multidrug-resistance 2 knockout mice (37).

Inhibitors of HSP90, 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) and geldanamycin, were suggested as a new class of senolytic candidates from the screening of 97 autophagy regulators in oxidative stress-induced senescent Ercc1−− mouse embryonic fibroblasts (MEFs) (38). These HSP90 inhibitors induced apoptosis of senescent MEFs, murine mesenchymal stem cells (MSCs), IMR-90, HUVECs, and WI-38 cells, induced by oxidative stress, irradiation, or replication, in vitro. They selectively eliminated p16-positive cells, and thereby delayed the onset of several age-related symptoms, and ultimately lengthened the health span of Ercc1−Δ-progeroid mice (38).

In addition to quercetin, natural phytochemicals, piperlongumine (PL) and fisetin, were reported to have senolytic activities in in vitro experiments. PL preferentially induced apoptosis in human WI-38 fibroblasts senesced by ionizing radiation, replicative exhaustion, or ectopic expression of the oncogene Ras, through an ROS-independent pathway (39). Fisetin selectively killed IR-induced senescent HUVECs, but not senescent IMR90 or pre-adipocytes (36). Quercetin-3-D-galactose (Q3G) has been suggested to be a potential senolytic agent, that was reported to kill senescent endothelial cells, but not HUVECs (40).

UBX0101, a small molecule inhibitor of the MDM2/p53 protein interaction, was revealed to be a potent senolytic candidate (26). Intra-articular injection of UBX0101 eliminated SCs accumulated in the articular cartilage and synovium, and resulted in attenuation of the development of post-traumatic osteoarthritis (OA) in aged mice (26). UBX0101 also cleared SCs by inducing apoptosis and improved the cartilage-forming ability of chondrocytes from human OA tissue (26). UBX0101 is the first senolytic under Phase 1 clinical trial in patients with OA of the knee (https://clinicaltrials.gov/ct2/show/NCT03513016).

In addition to primary cells, senolytics targeting cancer cells have been also proposed. Panobinostat, an FDA approved HDAC inhibitor, was identified to have senolytic activity in chemotherapy-induced senescence of cancer cells, non-small cell lung cancer, and head and neck squamous cell carcinoma cell lines (41). During standard chemotherapy, senescence-associated events, such as decreased histone acetylation, enhancement of Bcl-2 family proteins, and SASP production occurred in cancer cells (42, 43). The latter events are a biomarker of senescence and a target of senotherapeutics. Chemotherapy-induced senescence has reported to be involved in the increased invasion of cancer cells, due to epithelial-to-mesenchymal transition in thyroid cancer (42), as well as acquisition of stem-cell-related properties in B-cell lymphoma (43). Thus, senolytics targeting senescent cancer cells might be a new strategy for treatment cancer metastasis and cancer stemness.

Forkhead box protein O4 (FOXO4) was identified as a pivotal protein involved in the viability of SCs. Using bioinformatic analysis of RNA sequence data from IR-induced senescent IMR90 cells, FOXO4-D-retro-inverso (FOXO4-DRI) peptide was demonstrated to be a new class of senolytic candidates (44). FOXO4-DRI peptide blocked the interaction of FOXO4 and p53 in senescent cells, which induced apoptosis of senescent IMR90 cells and HUVECs. Administration of the peptide improved fitness, hair density, and kidney function in both Xpd-progeroid and naturally aged mice (44).

Based on the countable lists of senolytics candidates, research on senolytics is still in its infancy, but growing rapidly. Since most senolytics target known proteins, such as p53, a tyrosine kinase, HSP90, Bcl-2, and Bcl-xL, elucidation of novel targets specific to CS is necessary for further development of senolytics. In addition, senolytics demonstrated cell-specific effects in killing SCs, suggesting CS might be differentially regulated depending on cell or tissue-specific factors. Further unbiased exploration of senolytics using chemical libraries or drug repositioning might contribute to the development of novel senolytics, as well as to the elucidation of novel mechanisms of CS.

SENOMORPHICS

Senomorphics is a wide range of agents that can modulate the phenotypes of SCs to those of young cells through interfering with senoinflammation/inflammaging, senescence-related signal pathways, and SASP, without induction of SC apoptosis (Table 2). Senomorphics include previous anti-aging or anti-senescence compounds, such as telomerase activator (45), CRMs (7), caloric restriction diets (8), sirtuin activators (46), mTOR inhibitors (47), antioxidants (48), anti-inflammatory agents targeting senoinflammation or inflammaging (49), autophagy activators (12), and proteasome activators (50). This review will not cover the aforementioned anti-aging or anti-senescence agents as senomophics. Instead, we have included recent results on agents exhibiting senomorphic activity, based on selective markers of cellular senescence, such as SASP and SAβG in in vitro and in vivo experimental models.

Table 2

Senomorphic candidates

Agents	Target pathway	Effects	Ref.
NBD peptide	IKK/NFB pathway	Delaying aging symptoms and chronic diseases in Ercc1−/Δ-progeroid mice	54
JAK inhibitor (ruxolitinib)	JAK (Janus kinase) pathway	Alleviation of the SASP and frailty in old mice	55
KU-60019	ATM kinase	Functional recovery of senescent fibroblasts through lysosomal-mitochondrial axisAcceleration of cutaneous wound healing in aged mice	56
JH4	Progerin/lamin A/C	Alleviation of nuclear deformation and reduction of senescence markers in HGPS and aged cellsMitigation of age-related pathologies and extension of lifespan in the HGPS-progeroid mice	58
Juglanin	Not reported	Inhibition of doxorubicin-induced senescence of HDFs and HUVECs and replicative cellular senescence of HDFs	59
Quercetin-3-O-β-D-glucuronide	Not reported	Inhibition of doxorubicin-induced and replicative senescence of HDFs and HUVECs	60
(−)-Loliolide	Not reported	Inhibition of doxorubicin-induced and replicative senescence of HDFs	61
Quercetagetin 3,4′-dimethyl ether	Not reported	Inhibition of doxorubicin-induced and replicative senescence of HUVECs	62
ESC-CM	PDGF/FGF pathway	Decreases in senescence phenotypes of HDFs and HUVECsAcceleration of the skin wound healing in mice	63
Mmu-miR-291a-3p	TGFBR2/p21 pathway	Inhibition of senescence phenotypes of HDFs and HUVECsAcceleration of the excisional skin wound healing in aged mice	64

Senoinflammation or inflammaging refers to chronic, sterile, low-grade, and unresolved inflammation characterized upon aging (51, 52). Nuclear factor-kappa B (NF-κB) activated in aging and ARDs, is a key transcription factor mediating senoinflammation or inflammaging and its activation has been linked to known regulators of the aging process, such as insulin/insulin-like growth factor (IGF)-1, FOXO, SIRT, mTOR and DNA damage (53). Therefore, inhibition of NF-κB has been suggested as a potential target of senomorphics. A peptide inhibitor of IKK, the NF-κB–activating kinase, reduced cellular senescence in vitro and in vivo, and delayed the age-related symptoms and pathologies of Ercc1-progeroid mice (54). In addition, SASP in SCs also plays an important role in senoinflammation or inflammaging. Thus, blocking of SASP in SCs might be a plausible target of senomorphics. SASP is regulated by the Janus kinase (JAK)/STAT pathway, and pharmacological inhibitors of JAK in SCs suppressed senoinflammation, alleviated age-related tissue dysfunction, and enhanced physical function in old mice (55).

Ataxia-telangiectasia mutated (ATM) kinase, a serine/threonine protein kinase activated by DNA double strand breaks, functions in the regulation of CS (2). Therefore, ATM kinase inhibitor, KU-60019, was identified as a potential senomorphic candidate. KU-60019 induced the functional recovery of the lysosome/autophagy system, coupled with mitochondrial functional recovery and metabolic reprogramming (56).

Progerin, a truncated form of lamin A protein involved in Hutchitson-Gilford progeria syndrome (HGPS), accumulated with progressive telomere shortening during CS of normal human fibroblasts, and suggested a causative role in CS (57). A small molecule, JH4, interfering binding of progerin and lamin A/C, has been shown to be a senomorphic candidate. JH4 alleviated nuclear deformation and reversed senescence markers, such as growth arrest and SAβG activity, in HGPS and aged cells. Administration of JH4 markedly mitigated several age-related pathologies and extended lifespan in HGPS-progeroid mice (58).

Natural compounds derived from plants, including juglanin (59), quercetin-3-O-β-D-glucuronide (60), (−)-loliolide (61), and quercetagetin 3,4′-dimethyl ether (62) were identified as senomorphic candiates, when they decreased SAβG and p53 levels in senescent HDFs and HUVECs.

Embryonic stem cells (ESCs) and ESC conditioned medium (CM) have been suggested as a source of anti-aging interventions that modulate the phenotypes of SCs. ESC-CM and ESC-CM derived factors, such as growth factor and miRNAs, reportedly might also be senomorphic candidates. ESC-CM markedly improved the phenotypes of SCs in HDFs and HUVECs, through a PDGF-FGF mediated pathway and accelerated wound healing in an in vivo mouse model (63). In addition, mmu-miR-291a-3p, enclosed in exosomes secreted from ESCs, was found to mitigate the phenotypes of SCs in HDFs and HUVECs, through a transforming growth factor beta receptor 2 (TGFBR2)-p21 pathway, and accelerated wound healing in aged mice (64).

SCs in tissues can activate both innate and adaptive immune responses, and are eliminated by the immune system to maintain tissue homeostasis mainly, through the DNA damage response (65). Clearance of SCs contributed to the regulation of tissue homeostasis, such as wound healing (66), hepatic fibrosis (67), and embryonic/placenta development (68). However, inefficient clearance of SCs due to aging of immune system or senescence immunosurveillence was shown to facilitate their accumulation in various tissues with age, and led to aging and ARDs (65). SCs revealed upregulation of MHC class I polypeptide-related sequence A (MICA) and UL16 binding protein 2 (ULBP2), ligands of an activating natural killer (NK) cell receptor (NKG2D), which induced NK-mediated clearance of SCs and decreased liver fibrosis (69). Dipeptidyl peptidase 4 (DPP4) was selectively upregulated in the cell membrane of senescent fibroblasts, but not in proliferating cells or DPP4-positive SCs preferentially eliminated by antibody-mediated NK cell-mediated cytotoxicity, and suggested a possible immunotherapeutic strategy for targeting SCs (70) (Fig. 1). In addition to NK cells, CD4+ T cells and macrophages were also involved in clearance of SCs, and prevented tumor development (71) and their contribution to embryonic development (68). Since NKG2D ligands are also expressed in many cancer cells, strategies to improve immunosurveillance already being developed as cancer therapy, might be repurposed to target SCs for the alleviation of aging and ARDs (18, 72, 73) (Table 3). T cells engineered to express the NKG2D chimeric antigen receptor (CAR), which recognizes NKG2D ligands on the surface of SCs, may be used to target SCs (65). CD9 is upregulated in the cell membrane of SCs (74), and CD9 antibody conjugated nanoparticles or liposomes preferentially delivered drugs to SCs and inhibited phenotypes of SCs in HDFs (75, 76). Therefore, antibody-mediated targeted drug delivery to SCs represents another immunotherapeutic strategy against SCs. Although some cell surface proteins preferentially upregulated in SCs have been shown to be involved in immune-system mediated clearance of SCs, more cell membrane proteins specific to diverse SCs should be investigated. Their identification would contribute to the development of senescence vaccines, targeting senescence-specific antigens, and promote development of novel strategies for immune-system mediated clearance of SCs.

Table 3

Immune-system mediated clearance of SCs

Surface proteins	Expression	Therapeutic cells	Ref.
MICA, ULBP2	Replicative, oncogene-induced, and DNA damage-induced senescent fibroblasts	Clearance of SCs by NK cells	69
DPP4	Senescent fibroblasts	Clearance of SCs by NK cells	70
CD9	Replicative and doxorubicin-induced senescent HUVECs and HDFs	Delivery of senomorphics by CD9-antibody conjugated nanoparticles and liposomes	7576

CONCLUSION

Recent accumulating evidence has suggested a causal linkage between CS, and aging and ARDs, and has led to the development of senotherapeutics targeting SCs. These senotherapeutics are classified as senolytics, senomorphics, and immune-system mediators of the clearance of SCs, and represent an emerging strategy of aging intervention for healthy aging, and prevention and treatment of ARDs. Similar to chemotherapeutics, the development of novel senotherapeutics must be more active and promote aging research on the mechanisms of CS regulation to identify novel targets. However, additional crucial issues must be overcome before senotherapeutics are applied in clinical practice. Although preclinical animal experiments revealed no significant side effects of some senolytics, further in-depth and careful analyses on potential adverse ef fects of long-term administration of senotherapeutics is essential for its successful application in healthy aging and ARDs of humans. Occasionally, imagination becomes realty. In 1997, GATTACA, a science fiction (SF) film directed by Andrew Niccol, highlighted a eugenics issue in genetically modified babies in a not-too-distant future society. In 2010, he released other SF film, IN TIME, in which people are genetically engineered to stop aging on their 25th birthday in 2169. What do you think of the two SF films? Are they still fantasy? In the future, senotherapeutics will be available in markets and contribute to healthy aging and prevention and treatment of ARDs.